Longevity research has gained momentum in recent years, focusing not only on extending lifespan but also on improving health during the latter stages of life. This field, often referred to as “gerotherapeutics,” aims to delay aging-related diseases and boost overall vitality.
The Role of Longevity Investors Conference
The Longevity Investors Conference, an annual event held in Switzerland, has become a crucial hub for investors, scientists, and companies involved in the anti-aging industry. The event emphasizes the latest trends, opportunities, and scientific breakthroughs in longevity research. At this conference, leaders from diverse fields discuss groundbreaking ideas and the future of gerotherapeutics.
FDA-Approved Drugs with Longevity Benefits
Four key FDA-approved drugs have been identified as promising candidates in reducing overall mortality. These drugs not only treat specific diseases but also address fundamental aging mechanisms, enhancing “healthspan”—the period during which one remains healthy.
SGLT2 Inhibitors: Originally developed for managing diabetes, this drug has shown significant benefits in prolonging life by addressing key aging hallmarks like immunity and metabolism. It is now prescribed for both diabetic and non-diabetic patients due to its protective effects on the kidneys and cardiovascular system.
Metformin: A well-known diabetes medication, Metformin has demonstrated impressive results in extending lifespan by targeting multiple aging pathways, including metabolic and immune systems. It is now regarded as one of the most powerful drugs for aging intervention.
GLP-1 Inhibitors: Initially designed for diabetes and obesity management, these inhibitors not only promote weight loss but also have protective effects against cardiovascular and neurodegenerative diseases, such as Parkinson’s and Alzheimer’s.
Bisphosphonates: Primarily used for treating osteoporosis, these drugs also help reduce mortality by strengthening bones and potentially extending life.
Clinical Trials and Real-World Applications
Extensive clinical trials and studies have backed the use of these four drugs. For instance, SGLT2 inhibitors have shown up to a 30% reduction in mortality, and this number increases to 50% in patients who consistently follow treatment. The versatility of these drugs, such as their application beyond diabetes to kidney and cardiovascular disease, makes them invaluable in the gerotherapeutic field.
Hallmarks of Aging: The Scientific Framework
The effectiveness of these drugs is linked to their ability to target the “hallmarks of aging.” These hallmarks include metabolic imbalances, inflammation, and cellular degeneration, all of which contribute to the aging process. By addressing these factors, the drugs not only treat diseases but also reduce the overall aging burden.
Future Directions
While these drugs can extend the average lifespan by a few years, personalized approaches and better combinations of therapies will be needed to push human longevity even further. As research progresses, it is likely that more FDA-approved drugs will be repurposed for longevity, with better precision in targeting specific hallmarks of aging.
Conclusion Diagram
Reference:
This summary is based on the original video titled “Four FDA-approved drugs decrease overall mortality in humans,” presented by Dr. Nir Barzilai at the Longevity Investors Conference. You can watch the full video here.
Medical Disclaimer:
This article is for educational purposes only and should not be considered medical advice. Consult a healthcare professional before starting any new treatment or medication. The drugs and information mentioned here may not be suitable for all individuals.
